Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI problems a result of the inhibition of the synthesis of gastroprotective brokers which include PGE2 as well as other prostaglandins. This inhibition contributes to lowered mucin manufacturing by gastric epithelial cells, less bicarbonate secretion, and fewer epithelia